

CH CENTER 1600/290

In re Application of: Gennady MERKULOV et al. Art Unit: 1646

Serial No.: 09/768,781

Examiner: N. Basi

Filed: January 25, 2001

Atty. Docket: CL001057CIP

For: ISOLATED HUMAN TRANSPORTER PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN TRANSPORTER PROTEINS, AND USES THEREOF

Statement Regarding Duty to Disclose Information Material To Patentability Under 37 CFR 1.56 (a) and (b)

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Applicants hereby notify the US Patent and Trademark Office of the documents listed on the attached PTO Form SB/08A, which may be deemed relevant to the patentability of the claims of the above application. One copy of each of the listed documents is submitted herewith. The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application.

The undersigned states that each item listed on the attached PTO Form SB/08A was first cited in a communication from a Foreign Patent Office in the above application's foreign counterpart or not known to the Undersigned for more than three months prior to the filing of this Information Disclosure Statement.

No fee is due for this IDS Submission. However, the Office is authorized to charge any other necessary fees related to the processing of this application to Deposit Account No. 50-0970.

Respectfully submitted,

CELERA GENOMICS

Lin Sun-Hoffman, Ph.D., Reg No. 47,983

Date: July 15, 2003

Celera Genomics Corporation 45 West Gude Drive, C2-4#21 Rockville, MD 20850

Tel: 240-453-3628 Fax: 240-453-3084

PTO/SB/05A (10-01)

Approved for use through 10/31/2002. OMB 0551-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of

Complete if Known			
Application Number	09/768,781		
Filing Date	January 25, 2001		
First Named Inventor	Gennady MERKULOV et al.		
Art Unit	1646		
Examiner Name	N. BASI		
Attorney Docket Number	CL001057CIP		

			U.S. PATE	ENT DOCUMENTS	•	
Examiner Initials		Document Number Number - Kind Code ² (if known	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		US-				
		us-				
	ļ	US-	an and a special parties of the second second	. 7,		
		US-			RECEIVED)
		US-		er i Valadia de de de la momentación de la decención de la dec	DECEIVE	
		US-	or an annual contract of the c	and the state of t	<u> </u>	
		US-			JUL 1 6 2003	
		US-			JULIOZ	
		US-			- 1000)
	ļ,	US- US-			TECH CENTER 1600	4
		US-				
		US-				
		US-	. , , , , , , , , , , , , , , , , , , ,			
		US-				
		us.				
		US-				
6. 		US-				
		US-				
	l	us-				

FOREIGN PATENT DOCUMENTS						
Examiner Cite Foreign Patent Document Initials No. 1 Country Code 3 - Number 4 - Kind Code 5 (if known)	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages	
		Applicant of Cited Document	or Relevant Figures Appear	T6		
		WO 01 55343 A	08/02/2001	Human Genome Sciences		Ι.
		WO 01 90304 A	11/29/2001	Human Genome Sciences		<u> </u>
. ,		an market and the system made transcenting company of the content		and the latter than the companion was believing these and administrations of the control was about the control was to be	MARIE 1947 - P. Cresche Marie Micro CAR - LAR - LARGE LYRIGH SPECE AL CHEMICALLY SE GRANADA	
				ng kanagan tank kanagangan gangan dang mapikan pangan kanagan dan pengangan	er - 1914 (ferrer 14.) - 200 Ministration - 1924 is as an	
		m in the common common the majorate standard and standard in the six decision and the		and the same same and a second property of the same same same same same same same sam		† —
1 7 7 7 7				remonife and their constant state of the people design	. The property of the second o	
		t made a final and make a kank in plane and income administration to the anomalous companies and the same and in			an anyone continue access company to access continue	l
					, natural time and mandematically a few times, they make I are the artists of a sec	1
	- · - · · - ·	The transport of the first and the contract first contract and contrac			and the second second grade and the second s	ļ
		en el men el mesorio, el mismo moderno moderno mesor de el mismo de el mesor d		TO THE THE PERSON NAMED AND ADDRESS OF THE PERSON NAMED AND AD		

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

31 CE +

Substitute for form 1449B/PTO

Sheet

Examiner

Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
2 of 2

Cor	mplete if Known	
Application Number	09/768,781	
Filing Date	January 25, 2001	
First Named Inventor	Gennady MERKULOV et al.	
Group Art Unit	1646	
Examiner Name	N. BASI	
Attorney Docket Number	CL001057CIP	

/		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
		Database FASTA 'Online! Database accession No. Z73417. XP002235483.		
		Database BLASTP 'Online! Database accession No. P51811. XP002235485.		
		Database FASTA 'Online! Database accession No. Q9QXY7. XP002235486.		
NEW YORK IS A SEC.		Ho Mengfatt et al. "Isolation of the Gene for McLeod Syndrome that Encodes a Novel Membrane Transport Protein." Cell. Vol. 77, No. 6, 1994, Pages 869-880. XP001146547.		
		Collec Emmanuel et al. "Structure and Expression of the Mouse Homologue of the XK Gene." Immunogenetics. Vol. 50, No. 1-2, October 1999. Pages 16-21. XP002235481. Lee S et al. "The Kell Blood Group System: Kell and XK Membrane Proteins." Seminars in Hematology. United States APR 2000. Vol. 37, No. 2, April 2000. Pages 113-121.	-	
9 - 1 194 604		XP009008315.		
		International Search report dated April 24, 2003.	-	-0
. , ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	ļ .	REC	EIY	ED
		JUL	16	coolse cools
		REC! JUL TECH CE	NTE	190015
11 day 20 10 1				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date

Considered

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.